scispace - formally typeset
V

Venkata Satish Kumar Mattaparthi

Researcher at Tezpur University

Publications -  38
Citations -  188

Venkata Satish Kumar Mattaparthi is an academic researcher from Tezpur University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 6, co-authored 29 publications receiving 122 citations. Previous affiliations of Venkata Satish Kumar Mattaparthi include Indian Institute of Technology Guwahati.

Papers
More filters
Journal ArticleDOI

Daboxin P, a Major Phospholipase A2 Enzyme from the Indian Daboia russelii russelii Venom Targets Factor X and Factor Xa for Its Anticoagulant Activity

TL;DR: This is the first report of a phospholipase A2 enzyme from Indian viper venom which targets both factor X and factor Xa for its anticoagulant activity.
Journal ArticleDOI

Bis- and mixed-ligand copper(II) complexes of nalidixic acid the antibacterial drug: Mode of nalidixate coordination determines DNA binding and cleavage and cytotoxicity

TL;DR: DNA docking studies reveal that 2 bound to DNA undergoes interesting coordinative distortions more than 1, causing more significant changes in DNA host, and displays oxidative DNA cleavage more prominent than [Cu(en)2]2+, by generating OH radicals, and shows poor cytotoxicity towards A549 lung cancer cell lines.
Journal ArticleDOI

Computational investigation on the effect of Oleuropein aglycone on the α-synuclein aggregation.

TL;DR: The findings in this study substantiate the effect of OleA on the structure and stabilization of α-synuclein monomer that subsequently favors the growth of stable and nontoxic aggregates.
Journal ArticleDOI

Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications

TL;DR: Sarma et al. as mentioned in this paper carried out molecular docking studies of compounds from the FDA approved drug library and passed phase-1 drug libraries with ten therapeutic targets of COVID-19 and showed that known drugs, including nine anti-inflammatory compounds, four antibiotics, six antidiabetic compounds, and one cardioprotective compound, could effectively inhibit multiple therapeutic targets.